NeuroDex

NeuroDex is a private, pre-revenue diagnostics company founded in 2019, specializing in biomarker development for neurological disorders through its neuron-derived exosome (NDE) technology. The company offers a suite of biomarker services and panels targeting key pathological proteins (e.g., α-Syn, TDP-43, Tau) to support pharmaceutical partners in clinical trials and translational research. With a team led by CEO/CSO Erez Eitan and operations in Boston, NeuroDex positions itself at the intersection of advanced diagnostics and the growing precision neurology market, though it faces risks typical of early-stage biotechs, including platform validation and funding needs.

Proprietary platform for isolating and analyzing neuron-derived exosomes (NDEs) from blood plasma to serve as a liquid biopsy for neurological disorders. The platform uses immunoassays and RNA sequencing to measure disease-relevant proteins (e.g., α-Syn, TDP-43, Tau) and RNA from brain-specific vesicles.

NeuroDex competes with other companies developing blood-based biomarkers for neurology, including Quanterix (SIMOA technology), C2N Diagnostics, and biopharma companies with internal biomarker programs. Its specific focus on neuron-derived exosomes differentiates it, but it faces competition from both established diagnostic firms and academic research driving the field forward.